Prognostic value of tumor markers, NSE, CA125 and SCC, in operable NSCLC Patients
about
Elevated serum annexin A1 as potential diagnostic marker for lung cancer: a retrospective case-control study.Identification and verification of Hsp90-beta as a potential serum biomarker for lung cancer.Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers.Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancerClinical significance of joint detection of serum CEA, SCCA, and bFGF in the diagnosis of lung cancer.Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer.Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancerMUC16 contributes to the metastasis of pancreatic ductal adenocarcinoma through focal adhesion mediated signaling mechanism.Reduced Expression of FADS1 Predicts Worse Prognosis in Non-Small-Cell Lung CancerPredictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer.Increased stathmin in serum as a potential tumor marker for lung adenocarcinoma.Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.Systematic Correlation Analyses of Circulating Tumor Cells with Clinical Variables and Tumor Markers in Lung Cancer Patients.Overexpression of Neuron-Specific Enolase as a Prognostic Factor in Patients with Gastric Cancer.CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma.Prognostic impact of cytological fluid tumor markers in non-small cell lung cancer.
P2860
Q34420604-BEB625B7-7669-45E4-8710-386C7A923266Q34704972-CEBB092A-352F-42BB-9A6B-4991D71C0635Q35200656-563FEE4A-3B3C-46A6-91B0-AB8E7C137F44Q35633965-7ED0F188-995B-4E52-9D3B-C007513AF794Q36095389-54F3C997-5674-4D47-9F20-D340C9F2642CQ36630663-6F1A7858-C673-44E3-8DD5-FDFD17E1D337Q36740905-D9B9D6AB-E6F2-451D-9619-1179FE15223CQ37033307-5E4A817B-5CDA-469B-83B2-31E8143BB331Q37067991-9B3845EB-4F23-4682-8363-F05A2D20C804Q37295811-654349A8-EA22-4465-BF62-65E7BF5B72B5Q38718071-42F0D96D-49D2-40C6-8F0E-23B8DA774D71Q38844281-6F3A4021-0DCB-4DE0-8F87-9FAA2F9413FCQ38947077-EA3F9FD6-C381-4513-938D-268E6EAE38A3Q41721622-03AE69B5-B026-407D-9056-459CD1593FE1Q42052260-C8CE7283-45F4-4051-8ABE-3156DED70311Q47161899-3FDF6486-41D7-418B-8E21-AB4DEDC9A8BBQ53323484-D5D766FE-F04A-4D36-912E-CB9A78BA7A6D
P2860
Prognostic value of tumor markers, NSE, CA125 and SCC, in operable NSCLC Patients
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prognostic value of tumor markers, NSE, CA125 and SCC, in operable NSCLC Patients
@en
Prognostic value of tumor markers, NSE, CA125 and SCC, in operable NSCLC Patients.
@nl
type
label
Prognostic value of tumor markers, NSE, CA125 and SCC, in operable NSCLC Patients
@en
Prognostic value of tumor markers, NSE, CA125 and SCC, in operable NSCLC Patients.
@nl
prefLabel
Prognostic value of tumor markers, NSE, CA125 and SCC, in operable NSCLC Patients
@en
Prognostic value of tumor markers, NSE, CA125 and SCC, in operable NSCLC Patients.
@nl
P2093
P2860
P356
P1476
Prognostic value of tumor markers, NSE, CA125 and SCC, in operable NSCLC Patients
@en
P2093
Dangfan Yu
Guojun Chen
Taifeng Liu
P2860
P304
11145-11156
P356
10.3390/IJMS140611145
P407
P577
2013-05-27T00:00:00Z